Search Results

Foundation Medicine, Inc., announced the U.S. launch of FoundationOne®RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes.

Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation.

Foundation Medicine, Inc., announced that 22 new pieces of research from its robust oncology diagnostics portfolio will be presented at the 2024 American Society of Clinical Oncology Annual Meeting from May 31 to June 4 in Chicago.

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, and Foundation Medicine, Inc. are pleased to announce a partnership aimed to impact the care of patients with late-stage colorectal cancer undergoing surgery.

Foundation Medicine, Inc., announced that it has formed a collaboration with Repare Therapeutics, a leading clinical-stage precision oncology company, to provide prospective genomic profiling to patients in Repare’s ongoing Phase I/Ib MYTHIC study of lunresertib alone or in combinations in genomically-defined patient populations.

Foundation Medicine, Inc., announced the appointment of Roche executive, Dan Malarek, as Chief Executive Officer.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Foundation Medicine Inc., announced the launch of the research use and investigational use versions of FoundationOne®RNA, its broad tissue-based RNA test.